Physician profile
Bryan Michael Burt
NPI 1396902052
$137,655.81
in general payments reported to CMS, 2019-2025
14 companies · $1,864 in 2025
The $1,864 reported for 2025 was more than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,961 · 2020: $11K · 2021: $43K · 2022: $43K · 2023: $27K · 2024: $9,457 · 2025: $1,864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $24K · Travel and Lodging: $5,621 · Food and Beverage: $4,127 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $24,081.84 |
| Travel and Lodging | $5,621.14 |
| Food and Beverage | $4,126.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $98,884.87 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Astrazeneca Pharmaceuticals LP | $27,286.58 | 2019-2025 | Tagrisso |
| Medtronic, INC. | $6,508.65 | 2022-2025 | Signia, V-Loc 180, Ligasure |
| Fujirebio Diagnostics, Incorporated | $2,400.00 | 2019 | |
| Covidien LP | $1,500.00 | 2020 | |
| On Target Laboratories, INC | $296.95 | 2024 | Cytalux |
| Genentech USA, INC. | $203.74 | 2022-2024 | Alecensa |
| Baxter Healthcare | $174.24 | 2022-2023 | Preveleak |
| Zimmer Biomet Holdings, INC. | $140.02 | 2019-2022 | |
| Atricure, INC. | $139.68 | 2022-2023 | |
| Abbott Laboratories | $71.42 | 2022 | |
| Ethicon US, LLC | $34.49 | 2024 | Harmonic, Echelon Endopath |
| Galvanize Therapeutics, INC | $15.17 | 2024 | Aliya System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Burt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.